ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Clinical trial NCT06439433 · COMPLETED

Trial details

NCT number: NCT06439433
Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cervical Intraepithelial Neoplasia Grade 2 Papillomavirus Infections p16 Protein

Start date: 2021-05-31
Primary completion: 2023-12-20
Enrollment: 119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.